Find out about the new DMTs available
Currently there are more disease modifying therapies (DMTs) available than ever. It is a really promising time for people diagnosed with MS, as more can be done to help manage the course of the disease. There are also now treatments available for all types of MS.
In the last couple of years, we have seen the licencing of ocrelizumab (Ocrevus) for primary progressive MS (PPMS) and siponimod (Mayzent) for secondary progressive MS (SPMS). Whilst there are many more drugs available for those with relapsing remitting MS (RRMS), this is still incredible progress in the treatment of a complex condition that affects people so differently.
Most recently we have seen the addition of ponesimod (Ponvory) and before that, ofatumumab (Kesimpta), both being approved during 2021.
Diroximel fumarate (Vumerity) was also approved in Scotland and more recently in England and Wales, with Northern Ireland to make their final decision soon.
Scotland also approved ozanimod (Zeposia) for RRMS last year. However, it has not been approved for England, Wales or Northern Ireland, as it was not found to be cost effective.
We hope this booklet provides the reader with enough information to make an informed decision about their treatment. Our helpline team are always on hand to discuss options.
Choosing a drug therapy can be a difficult decision to make and one that can be helped greatly by talking it through with someone else. Many factors, including lifestyle, need to be considered.
In cases when MS is highly active, choice may be limited, but this booklet will still provide information to understand why that drug is being suggested over others.
The world of drug therapy is always changing and there are many more potential drugs in development. We always recommend checking our website for all the latest news and information.
To read online or download, please click here.
If you would like to help inform our work, please have a look at our Virtual Insights Panel and consider joining. Our panel helps to ensure we are community led and that we are producing information that the MS community want.